Silicon Laboratories (SLAB) opened Q1 2026 with revenue of US$213.5 million and a basic EPS loss of US$0.48, as net income excluding extra items came in at a loss of US$15.9 million. The company has seen quarterly revenue move from US$166.2 million in Q4 2024 to US$177.7 million in Q1 2025, then to US$213.5 million in Q1 2026. Over the same quarters, EPS shifted from a loss of US$0.73 to a loss of US$0.94 and then to a loss of US$0.48. For investors, the key question is whether this top line performance can eventually support healthier margins and a clearer path toward earnings stability.

See our full analysis for Silicon Laboratories.

With the headline numbers on the table, the next step is to see how these results line up against the widely followed growth and risk narratives around Silicon Laboratories and where the story might need updating.

Trailing losses of US$50.3 million keep profitability in focus

• On a trailing 12 month basis to Q1 2026, Silicon Laboratories generated US$820.6 million in revenue and recorded a net loss excluding extra items of US$50.3 million, with basic EPS of US$1.53 loss.
• Bears point out that losses have grown at about 22.5% per year over five years and forecasts reviewed here do not show a return to profit within the next three years, which sits uneasily alongside higher expectations for future earnings.
  • The consensus narrative talks about earnings potentially reaching US$217.0 million by around 2029, yet the current trailing 12 month loss of US$50.3 million highlights how far current results sit from that scenario.
  • Even the more cautious group of analysts referring to a current loss of US$64.9 million and projecting US$72.3 million of earnings are still working off forecasts, while the recent EPS of US$1.53 loss over the last year confirms that the business is not yet at that stage.

Skeptics warn that the gap between today’s US$50.3 million loss and the earnings figures used in long term models is a key execution risk, especially if margin improvement takes longer than expected. 🐻 Silicon Laboratories Bear Case

Revenue growth forecasts versus current US$820.6 million run rate

• Revenue over the trailing 12 months to Q1 2026 stands at US$820.6 million, and external forecasts cited here point to annual revenue growth of about 14.46% from this base, compared with a 11.3% forecast for the wider US market.
• Supporters of the bullish view highlight expanding IoT deployments and wireless platforms as drivers of that growth outlook, and the current run rate provides some numerical backing to those claims while still leaving plenty to prove.
  • Consensus assumptions of revenue rising to roughly US$1.2b by around 2029 start from today’s US$820.6 million trailing figure, so actual growth from here would need to track close to the cited 14.46% rate to line up with that path.
  • The bearish cohort, which also references revenue growth around the mid teens, still anchors its view on the same basic pattern that revenue is expected to outpace the 11.3% market forecast even though profitability has not yet followed.

Bulls argue that the current US$820.6 million revenue base plus forecast 14.46% growth can support the longer term IoT story if execution holds up at this pace. 🐂 Silicon Laboratories Bull Case

Valuation tension at 8.7x P/S and US$216.54 per share

• Silicon Laboratories currently trades on a P/S of 8.7x, above the cited peer average of 7.9x and the US Semiconductor industry average of 8.3x, and the US$216.54 share price sits well above the DCF fair value of US$65.20.
• What stands out in the bearish narrative is how much growth and margin expansion would be needed to support both the current price and the analyst consensus target of US$222.86, given the premium P/S multiple and the gap to DCF fair value.
  • To align with the consensus target of US$222.86 from today’s US$216.54, investors would effectively be assuming that future earnings, including the hypothetical US$217.0 million figure discussed for 2029, become credible relative to the present loss making position.
  • The DCF fair value of US$65.20 is far below the current share price, so anyone focusing on discounted cash flows is looking at a very different implied return profile than someone anchoring on the analyst target of US$222.86.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Silicon Laboratories on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With the mixed tone of growth potential and ongoing losses in mind, act soon to review the full picture and weigh both sides of the story by using the 1 key reward and 1 important warning sign.

Explore Alternatives

Silicon Laboratories currently combines trailing losses, a lack of near term profitability in forecasts and a P/S of 8.7x that exceeds cited peer and industry averages.

If that mix of ongoing losses and a premium P/S multiple feels uncomfortable, take a few minutes to compare it with companies highlighted in the 44 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.